- Home
- WEC vs ALNY Comparison
WEC vs ALNY Comparison
Compare WEC & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEC
- ALNY
- Stock Information
- Founded
- WEC 1896
- ALNY 2002
- Country
- WEC United States
- ALNY United States
- Employees
- WEC N/A
- ALNY N/A
- Industry
- WEC Power Generation
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- WEC Utilities
- ALNY Health Care
- Exchange
- WEC Nasdaq
- ALNY Nasdaq
- Market Cap
- WEC 34.8B
- ALNY 39.6B
- IPO Year
- WEC N/A
- ALNY 2004
- Fundamental
- Price
- WEC $103.94
- ALNY $309.70
- Analyst Decision
- WEC Hold
- ALNY Strong Buy
- Analyst Count
- WEC 8
- ALNY 25
- Target Price
- WEC $104.88
- ALNY $324.96
- AVG Volume (30 Days)
- WEC 2.2M
- ALNY 849.2K
- Earning Date
- WEC 07-30-2025
- ALNY 07-31-2025
- Dividend Yield
- WEC 3.43%
- ALNY N/A
- EPS Growth
- WEC 12.23
- ALNY N/A
- EPS
- WEC 5.14
- ALNY N/A
- Revenue
- WEC $9,069,200,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- WEC $10.82
- ALNY $30.77
- Revenue Next Year
- WEC $5.03
- ALNY $30.51
- P/E Ratio
- WEC $20.25
- ALNY N/A
- Revenue Growth
- WEC 4.42
- ALNY 17.21
- 52 Week Low
- WEC $77.47
- ALNY $153.23
- 52 Week High
- WEC $111.00
- ALNY $317.54
- Technical
- Relative Strength Index (RSI)
- WEC 44.54
- ALNY 63.60
- Support Level
- WEC $103.03
- ALNY $295.82
- Resistance Level
- WEC $106.84
- ALNY $317.54
- Average True Range (ATR)
- WEC 1.37
- ALNY 7.74
- MACD
- WEC -0.16
- ALNY -0.67
- Stochastic Oscillator
- WEC 32.22
- ALNY 63.90
About WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 34% gas distribution, 10% electric transmission, and 7% unregulated renewable energy.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.